The Outcome of Molecularly Targeted Therapy after Surgical Treatment of Spinal Metastasis

The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We comp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-06, Vol.12 (12), p.3920
Main Authors: Sugita, Shurei, Ogiso, Sawako, Fujiwara, Masanori, Morita, Euan, Koyama, Takuma, Hozumi, Takahiro
Format: Article
Language:English
Subjects:
Bisphosphonates
Breast cancer
Brief Report
Care and treatment
Clinical medicine
Colorectal cancer
Diagnosis
Kidney cancer
Life expectancy
Medical prognosis
Metastasis
Molecular targeted therapy
Patient outcomes
Patients
Radiation therapy
Radiotherapy
Statistical significance
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate outcomes of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants comprised 164 patients who underwent surgical treatment of spinal metastasis, divided according to whether molecularly targeted therapy was performed. We compared survival, local recurrence of metastasis detected by imaging, the disease-free interval, relapses of neurological deterioration, and the ability to walk between groups. Molecularly targeted drugs were administered to 39 patients after surgery (TT group) and were not administered to 125 patients (non-TT group). Median survival was significantly longer in the TT group (1027 days) than in the non-TT group (439 days, < 0.01). Local recurrence occurred in 25 patients in the non-TT group and 10 patients in the TT group. The disease-free interval did not differ between groups. Neurological deterioration was observed in three patients in the non-TT group and no patients in the TT group. The ability to walk was preserved in 97.6% of patients in the TT group and 88% of patients in the non-TT group ( = 0.12). In conclusion, molecularly targeted drugs improve survival in patients with spinal metastasis but do not alter local control of metastatic tumors.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12123920